Ongoing eligibility for Bridge to Commercial Coverage Offer (Aimovig™ at no cost for up to 12 doses)


Eligible patient must have commercial prescription insurance, a valid prescription for Aimovig, previously failed another preventive migraine treatment, and participate in an insurance plan that requires a prior authorization or does not provide coverage for Aimovig. Bridge to Commercial Coverage Offer provides up to 12 doses to patient while insurance coverage is pursued for up to 24 months from enrollment, whichever occurs first. Once insurance approval is obtained, patient is no longer eligible for the offer. Offer is not renewable. By participating in this offer, patient acknowledges intent to pursue insurance coverage for Aimovig with their healthcare provider. Ongoing eligibility requires that patient has (i) a prior authorization or medical exception denied within 90 days of first use of offer, and (ii) an appeal of the prior authorization or medical exception denied within 180 days of first use of of fer. See full Terms and Conditions for more information.





+

Important Safety Information

Before starting Aimovig (erenumab-aooe), tell your healthcare provider about all your medical conditions, including if you are allergic to rubber or latex, pregnant or plan to become pregnant, breastfeeding or plan to breastfeed.

Tell your healthcare provider or pharmacist about all the medicines you take, including any prescription and over-the-counter medicines, vitamins, or herbal supplements.

What are possible side effects of Aimovig?

The most common side effects of Aimovig are pain, redness, or swelling at the injection site and constipation.

Tell your healthcare provider if you have any side effect that bothers you or that does not go away. These are not all of the possible side effects of Aimovig. Ask your healthcare provider or pharmacist for more information. Call your healthcare provider for medical advice about side effects.

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Click here for Full Prescribing Information and Patient Product Information.

Approved Use

Aimovig is a prescription medicine used for the preventive treatment of migraine in adults.